Hennion & Walsh Asset Management Inc. Has $1.66 Million Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Hennion & Walsh Asset Management Inc. increased its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 73.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 17,848 shares of the medical instruments supplier’s stock after acquiring an additional 7,559 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in LeMaitre Vascular were worth $1,658,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LMAT. Driehaus Capital Management LLC grew its position in LeMaitre Vascular by 52.2% in the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after acquiring an additional 90,573 shares in the last quarter. F M Investments LLC bought a new stake in LeMaitre Vascular in the second quarter worth $7,443,000. Nicholas Investment Partners LP bought a new position in LeMaitre Vascular during the second quarter valued at about $3,900,000. Janus Henderson Group PLC lifted its position in shares of LeMaitre Vascular by 554.7% in the first quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after buying an additional 47,218 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of LeMaitre Vascular by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock worth $87,914,000 after buying an additional 38,303 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

Insider Buying and Selling

In other news, Director David B. Roberts sold 3,063 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $85.64 on Friday. The firm has a fifty day moving average price of $89.29 and a two-hundred day moving average price of $82.14. LeMaitre Vascular, Inc. has a fifty-two week low of $44.27 and a fifty-two week high of $93.32. The company has a market cap of $1.92 billion, a PE ratio of 51.28, a price-to-earnings-growth ratio of 2.29 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The business had revenue of $55.85 million for the quarter, compared to the consensus estimate of $54.98 million. During the same period last year, the business earned $0.37 earnings per share. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. Analysts expect that LeMaitre Vascular, Inc. will post 1.86 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were paid a $0.16 dividend. The ex-dividend date was Thursday, August 15th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.75%. LeMaitre Vascular’s payout ratio is 38.32%.

Analyst Upgrades and Downgrades

LMAT has been the topic of a number of recent analyst reports. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. JMP Securities lifted their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Lake Street Capital began coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price on the stock. Finally, Barrington Research restated an “outperform” rating and set a $92.00 price target on shares of LeMaitre Vascular in a report on Friday, September 20th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $94.67.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.